2023-11-24 09:01:00
The Novo Nordisk site in Chartres is used to announcements. At the start of the year, the Novo facility in Chartres welcomed Roland Lescure, Minister Delegate for Industry, on the occasion of an investment announcement of €130 million. But this time the factory was entitled to a presidential trip with the arrival of Emmanuel Macron on the Eure-et-Loir site. It must be said that the investment is significant and rare in the French pharmaceutical industry.
The Danish laboratory is in fact preparing to invest an additional 2.1 billion euros in the production of its treatments once morest chronic diseases such as diabetes and obesity. “An unprecedented amount for your company, for the pharmaceutical industry in France and one of the largest industrial investments this year”appreciated Emmanuel Macron, received in the new spaces announced at the start of the year and transformed for the occasion into a giant reception room.
“This significant investment announced confirms the importance of our French site, one of our strategic production sites, as a cornerstone of the growth we are experiencing as a company”recalled Lone Charlotte Larsen, director of the Chartres site.
In detail, the laboratory plans to increase “considerably” the site’s aseptic and finished product production capacities, in addition to an extension of the current quality control laboratory and the installation of new equipment. Ultimately, the total surface area of the installation will be doubled, to reach 230,000 m². In total, the laboratory hopes to recruit 500 additional people, while the site employs around 1,600 people. The first construction stages have been launched and will be gradually finalized between 2026 and 2028.
An ever-increasing demand for antidiabetics
The investment announcement comes at a particularly favorable time for new molecules once morest diabetes which are also gaining approval in the fight once morest obesity.
The two laboratories that manage to position themselves on this market, Novo Nordisk with its semaglutide and Lilly with its tirzepatide, continue to inject liquidity to increase their capacities.
Lilly has just announced a massive investment in Germany to create a new factory, one month following having dedicated a budget of €160 million for its Alsatian site in Fegersheim (Bas-Rhin). Novo Nordisk has also invested massively in its own production facilities with €5.6 billion injected into Denmark to support the manufacturing of its new anti-diabetics. “Our continued investments in our production sites around the world show that we believe in our current and future product portfolio and its relevance for people with serious chronic diseases”added Henrik Wulff, executive vice president, Product supply, Quality & IT, Novo Nordisk.
With €2.1 billion invested in Chartres, the French site is doing well. An additional step for a site which has continued to grow to the point of doubling in size in ten years. “I visited the site seven years ago as Minister of the Economy. I have wonderful memories of it but a lot of things have changed”, recalled Emmanuel Macron. With this new investment, the face and size of the site should be further transformed in the years to come.
Selected for you
1700887252
#Novo #Nordisk #signs #unprecedented #investment #pharma #injects #billion #Chartres #site
